Investing News NetworkMay 21, 2024Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the 'Company' or 'Sona') is pleased to advise that it has appointed Dr. Carman Giacomantonio MD, MSc., FRCSC (Cav.) to be the Company's Chief Medical Officer. Dr. Giacomantonio is a practicing Surgical Oncologist at the QEII Health Sciences Centre and a Professor of Surgery at Dalhousie University.

投资新闻网2024年5月21日SONA Nanotech Inc.（CSE:SONA）（OTCQB:SNANF）（“公司”或“SONA”）很高兴地告知，它已任命Carman Giacomantonio博士为理学硕士。，FRCSC（Cav。）担任公司首席医疗官。贾科马安东尼奥博士是QEII健康科学中心的执业外科肿瘤学家，也是达尔豪西大学的外科教授。

Dr. Giacomantonio leads a productive translational research group at Dalhousie University and has successfully initiated two clinical trials in cancer immunotherapy. He is widely published in the field of cancer immunobiology and immunotherapy research, and a recognized innovator in the field of intra-tumoral cancer immunotherapy.

贾科马安东尼奥博士领导着达尔豪西大学一个富有成效的转化研究小组，并成功启动了两项癌症免疫治疗临床试验。他在癌症免疫生物学和免疫治疗研究领域广泛发表论文，是肿瘤内癌症免疫治疗领域公认的创新者。

Dr. Giacomantonio currently serves on Sona's Advisory Board and is the Principal Investigator for Sona's pre-clinical studies using Sona's gold nanorods in its Targeted Hyperthermia Therapy ('THT') for triple negative breast cancer, melanoma, and colorectal cancer. Sona is extremely excited to have Dr.

Giacomantonio博士目前在Sona的咨询委员会任职，是Sona临床前研究的主要研究者，该研究使用Sona的金纳米棒进行针对三阴性乳腺癌，黑色素瘤和结直肠癌的靶向热疗（“THT”）。索纳对拥有博士非常兴奋。

Giacomantonio's vision and experience to lead the development of our THT-based immunotherapy towards first-in-human clinical trials.Dr. Giacomantonio commented, 'The opportunity to work with Sona to develop a cancer treatment using its unique technology represents a culmination of my life's work to better harness the body's innate immune system to defeat cancer.Our ability to use Sona's therapy to improve the performance of immunotherapy drugs, as we are seeing in our mouse models, portends tremendous potential opportunities.

Giacomantonio的愿景和经验引领我们基于THT的免疫疗法朝着首次人体临床试验的方向发展。贾科马安东尼奥博士评论道：“有机会与索纳合作，利用其独特的技术开发出一种癌症治疗方法，这是我一生工作的一个高潮，可以更好地利用身体的先天免疫系统来战胜癌症。正如我们在小鼠模型中看到的那样，我们使用Sona疗法来改善免疫治疗药物性能的能力预示着巨大的潜在机会。

I'm excited that this appointment will allow me to be more directly involved in the planning and direction of moving it towards obtaining regulatory approvals and into clinical trials.'David Regan, CEO of Sona, commented, 'Carman brings not only his .

我很兴奋，这次任命将使我能够更直接地参与规划和指导，使其获得监管部门的批准并进入临床试验。”Sona首席执行官大卫·里根（DavidRegan）评论道：“卡曼带来的不仅仅是他的。